Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Ondine Biomedical, Inc. ( (GB:OBI) ) has shared an announcement.
Margaret Shaw, a Non-executive Director at Ondine Biomedical Inc., has increased her stake in the company by purchasing 30,000 shares at 12 pence each. This transaction reflects confidence in the company’s ongoing Phase 3 clinical trials and could signal positive expectations for its photodisinfection technology, which is poised for regulatory advancements and potential market expansion.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, also known as photodisinfection. With a range of investigational products, Ondine’s technology is in various stages of development, including a nasal photodisinfection system marketed as Steriwave® in Europe and Canada. The company is engaged in clinical trials for U.S. regulatory approval and aims to expand its product range to treat medical conditions such as chronic sinusitis and ventilator-associated pneumonia.
YTD Price Performance: 37.14%
Average Trading Volume: 525,352
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £48.48M
For an in-depth examination of OBI stock, go to TipRanks’ Stock Analysis page.
